Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases
Strategic Profile
RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development, with products based on several technology platforms addressing several disease targets for risk diversification. RedHill recently began a joint U.S. commercial launch of Talicia (H. pylori treatment) with Cumberland in February 2026.
Cyborg Score Rationale
RedHill shows solid pipeline progress and recent commercial activity (Talicia launch, RHB-102 advances), but faces significant operational headwinds including Nasdaq compliance violations (stockholders' equity requirement) and low analyst sentiment. Stock price weakness ($1.02 as of Feb 2026) and limited institutional ownership reflect market skepticism.
Top Insights
RHB-102 (ondansetron) shows multi-indication potential including GLP-1 GI side effects with 50% discontinuation rates at 3 months, representing up to $35B market opportunity by 2030.
Talicia (H. pylori) and Aemcolo (travelers' diarrhea) launched with commercial partner Cumberland, expanding U.S. market reach for core GI franchise.
Opaganib pipeline advancing in oncology (prostate cancer Phase 2 with Bayer support) and medical countermeasures (radiation, chemical/biological threats).
Company currently non-compliant with Nasdaq stockholders' equity requirements as of October 2025, raising potential delisting risk and restricting financing options.
Named Competitors
H. pylori treatments — Established market with competing therapies
Travelers' diarrhea treatments — Established generic market
GLP-1 side effect management — New competitive space targeting obesity medication adverse events
Recent Developments
(Feb 2026) RedHill and Cumberland launched full sales and operations for Talicia (H. pylori treatment) in U.S. market
(Jan 2026) Company planning Phase 2 proof-of-concept study for RHB-102 in GLP-1 GI side effects starting early 2026 under FDA 505(b)(2) pathway
(Oct 2025) Nasdaq Staff Determination notification of non-compliance with minimum stockholders' equity requirement; legal fee award from Kukbo case (>$10.5M total) remains subject to appeal until March 2026
Open the full interactive RedHill Biopharma Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.